Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

176 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diabetes remission and relapse following an intensive metabolic intervention combining insulin glargine/lixisenatide, metformin and lifestyle approaches: Results of a randomised controlled trial.
McInnes N, Hall S, Lochnan HA, Harris SB, Punthakee Z, Sigal RJ, Hramiak I, Azharuddin M, Liutkus JF, Yale JF, Sultan F, Smith A, Otto RE, Sherifali D, Liu YY, Gerstein HC; REMIT-iGlarLixi Collaborative Group. McInnes N, et al. Among authors: yale jf. Diabetes Obes Metab. 2023 Nov;25(11):3347-3355. doi: 10.1111/dom.15234. Epub 2023 Aug 14. Diabetes Obes Metab. 2023. PMID: 37580972 Clinical Trial.
Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study.
Houlden R, Ross S, Harris S, Yale JF, Sauriol L, Gerstein HC. Houlden R, et al. Among authors: yale jf. Diabetes Res Clin Pract. 2007 Nov;78(2):254-8. doi: 10.1016/j.diabres.2007.03.021. Epub 2007 May 9. Diabetes Res Clin Pract. 2007. PMID: 17490781 Clinical Trial.
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.
DREAM Trial Investigators; Dagenais GR, Gerstein HC, Holman R, Budaj A, Escalante A, Hedner T, Keltai M, Lonn E, McFarlane S, McQueen M, Teo K, Sheridan P, Bosch J, Pogue J, Yusuf S. DREAM Trial Investigators, et al. Diabetes Care. 2008 May;31(5):1007-14. doi: 10.2337/dc07-1868. Epub 2008 Feb 11. Diabetes Care. 2008. PMID: 18268075 Free article. Clinical Trial.
Effects of intensive glucose lowering in type 2 diabetes.
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT. Action to Control Cardiovascular Risk in Diabetes Study Group, et al. N Engl J Med. 2008 Jun 12;358(24):2545-59. doi: 10.1056/NEJMoa0802743. Epub 2008 Jun 6. N Engl J Med. 2008. PMID: 18539917 Free PMC article. Clinical Trial.
Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials.
Mount DL, Feeney P, Fabricatore AN, Coday M, Bahnson J, Byington R, Phelan S, Wilmoth S, Knowler WC, Hramiak I, Osei K, Sweeney ME, Espeland MA; Look AHEAD and ACCORD Research Groups. Mount DL, et al. Clin Trials. 2009 Oct;6(5):416-29. doi: 10.1177/1740774509344440. Epub 2009 Sep 8. Clin Trials. 2009. PMID: 19737845 Free PMC article.
Effects of medical therapies on retinopathy progression in type 2 diabetes.
ACCORD Study Group; ACCORD Eye Study Group; Chew EY, Ambrosius WT, Davis MD, Danis RP, Gangaputra S, Greven CM, Hubbard L, Esser BA, Lovato JF, Perdue LH, Goff DC Jr, Cushman WC, Ginsberg HN, Elam MB, Genuth S, Gerstein HC, Schubart U, Fine LJ. ACCORD Study Group, et al. N Engl J Med. 2010 Jul 15;363(3):233-44. doi: 10.1056/NEJMoa1001288. Epub 2010 Jun 29. N Engl J Med. 2010. PMID: 20587587 Free PMC article. Clinical Trial.
176 results